Balaxi Pharmaceuticals (BALAXI) Q4 24/25 earnings summary

Executive summary

• Achieved 21% year-over-year consolidated revenue growth in FY25, driven by expansion into new sales channels and geographies.

• Maintained leadership in branded generics in Africa and scaled rapidly in Latin America, supported by a robust distribution network.

• Approved audited standalone and consolidated financial results for Q4 and FY25, with unmodified audit opinions from statutory auditors.

• Provided update on first pharmaceutical formulation plant at Jadcherla, Hyderabad; machinery installed, validation ongoing, licence application submitted.

• Secured 85 new product registrations, expanding the portfolio to 915 products across seven countries.

Financial highlights

• FY25 consolidated revenue reached INR 292.56 crore, up 21.2% year-over-year; gross profit rose 12.6% to INR 126.86 crore.

• Consolidated net profit for FY25 was INR 27.67 crore, compared to INR 10.90 crore in FY24.

• Gross margin declined to 43.4% from 46.7% year-over-year; EBITDA fell 24% to INR 33.50 crore, with margin dropping to 11.5%.

• Q4 FY25 revenue grew 27.5% year-over-year to INR 76.27 crore; gross margin at 48.1%, EBITDA margin at 14.2%.

• Q4 FY25 PAT was INR 8.64 crore, down 21% year-over-year; EPS at INR 1.56.

Outlook and guidance

• Jadcherla plant validation expected to conclude by end of June 2025; manufacturing test licence anticipated soon.

• Plans to operationalize the Hyderabad manufacturing facility in FY26, enabling backward integration and improved cost efficiency.

• Aims to expand branded formulations in existing and new markets, and invest in regulatory filings for entry into higher-value markets.

• Focus on strengthening internal systems and supply chain resilience to support sustainable growth.